Elamipretide Improves Physical Fitness Compared to Natural Disease Course in Barth Syndrome, Analysis Shows
Elamipretide (MTP-131) improves physical fitness in people with Barth syndrome, as compared to the natural course of the disease, according to a new comparison using data from the Phase 2/3 TAZPOWER clinical trial. Stealth BioTherapeutics, the company that is developing elamipretide and which funded TAZPOWER, plans to…